DCPH: 38% | Deciphera Pharma shares are trading higher after the company announced its study of patients with TGCT met its primary and secondary endpoint.

DAWN: 9.5% | Day One Biopharmaceuticals shares are trading higher after the company announced the FDA accepted its NDA for tovorafenib in relapsed or progressive pediatric low-grade glioma, granted priority review and assigned a PDUFA date of April 30, 2024.

VYNE: 72% | VYNE Therapeutics shares are trading higher after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo.